Breast cancer : Zoledronic acid--more than just a bone drug
Several clinical trials have investigated the antitumour effect of bisphosphonates when used as adjuvant treatment for early stage breast cancer. Among these, the results of the AZURE trial, although negative,highlight the potential benefit of treatment with zoledronic acid in postmenopausal women with high-risk early stage breast cancer.
| Errataetall: |
CommentOn: Lancet Oncol. 2014 Aug;15(9):997-1006. - PMID 25035292 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Nature reviews. Clinical oncology - 11(2014), 10 vom: 10. Okt., Seite 564-5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mathew, Aju [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6XC1PAD3KF |
|---|
| Anmerkungen: |
Date Completed 15.12.2014 Date Revised 14.12.2023 published: Print-Electronic CommentOn: Lancet Oncol. 2014 Aug;15(9):997-1006. - PMID 25035292 Citation Status MEDLINE |
|---|
| doi: |
10.1038/nrclinonc.2014.152 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM241703581 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM241703581 | ||
| 003 | DE-627 | ||
| 005 | 20231227125028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/nrclinonc.2014.152 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1223.xml |
| 035 | |a (DE-627)NLM241703581 | ||
| 035 | |a (NLM)25200411 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mathew, Aju |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Breast cancer |b Zoledronic acid--more than just a bone drug |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2014 | ||
| 500 | |a Date Revised 14.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Lancet Oncol. 2014 Aug;15(9):997-1006. - PMID 25035292 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Several clinical trials have investigated the antitumour effect of bisphosphonates when used as adjuvant treatment for early stage breast cancer. Among these, the results of the AZURE trial, although negative,highlight the potential benefit of treatment with zoledronic acid in postmenopausal women with high-risk early stage breast cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Bone Density Conservation Agents |2 NLM | |
| 650 | 7 | |a Diphosphonates |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Zoledronic Acid |2 NLM | |
| 650 | 7 | |a 6XC1PAD3KF |2 NLM | |
| 700 | 1 | |a Brufsky, Adam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature reviews. Clinical oncology |d 2009 |g 11(2014), 10 vom: 10. Okt., Seite 564-5 |w (DE-627)NLM187524599 |x 1759-4782 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2014 |g number:10 |g day:10 |g month:10 |g pages:564-5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/nrclinonc.2014.152 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2014 |e 10 |b 10 |c 10 |h 564-5 | ||